$47.69
Fair Price Index
The fair price of a share represents the true value of the company's share based on its financial condition and performance. Unlike the current market price, which can fluctuate depending on the mood of the market, the fair price provides us with a better understanding of whether the share is truly advantageous.
To display the fair price of a share, you need to be a member of Bulios Black.
Profile
Novo Nordisk A/S (NVO) is a Danish pharmaceutical company specializing in the development, manufacturing, and sale of medicines for the treatment of diabetes and other endocrine and metabolic disorders. The company is one of the world's leading manufacturers of insulin and insulin-related medications, which are essential for diabetes treatment. Novo Nordisk also offers other pharmaceutical products for the treatment of obesity, hemophilia, and various endocrine disorders. The company emphasizes on research and innovation in the field of diabetes and other endocrine diseases and has long been committed to fighting diabetes and obesity. Novo Nordisk A/S has extensive international operations, and its products are available in more than 170 countries. Shares of Novo Nordisk A/S (NVO) could represent an intriguing investment opportunity for those who believe in the long-term demand for diabetes and metabolic medications.
Feed
This positive $NVO stock news is available only to Bulios Black members.
For me, it would definitely be $AMZN, $TTD and $NVO. I've been overbought these three stocks a lot lately because their price has been very low, but the fundamentals haven't changed, which I see as a great opportunity to increase my position.
As for the results, this week will probably be more interesting for me than the last one. A number of companies whose shares I hold in my portfolio will report results, and I expect bigger moves because they are growth stocks. I will be watching the results of $PLTR, $NVO, $AMD and $TTD.
Which companies' results will you be interested in?
💊 Novo Nordisk expands distribution of Wegova via telehealth. Hims & Hers shares jumped by more than 25%! Danish pharmaceutical giant Novo Nordisk $NVO is coming up with another move to accelerate sales of its weight loss drug Wegova. The drug will now also be available through telemedicine platforms such as Hims & Hers Health $HIMS, LifeMD, and including NovoCare's direct... Read more
Investors, which company in your portfolio do you understand its business best?
Each of us probably has a stock that we're really interested in, enjoy, and have gone deep into. For me, it's probably $GOOG, $ASML and $NVO - companies I've studied a lot and have a larger position in.
Novo Nordisk shares fell 9% today following news that the weight loss drug CagriSema was not as effective as expected in clinical trials. Investors may not be happy with such news, but on the other hand, this decline can be used to increase the position.
What do you think about this news? Are you buying $NVO after today's drop?
Both companies have very similar businesses and compete with each other. With $NVO, they may be at risk of tariffs that Trump might impose, and their drug may not be as popular in the US. Still, $NVO currently looks more interesting to me , which is why I've been shopping around this year. I think the stock is undervalued and the... Read more
European stocks have been relatively cheap lately, which has caught my eye, and I invested quite a bit in them last year. Currently my portfolio includes $ASML, $NVO, $MC.PA, plus Czech banks.
What European stocks do you have in your portfolio?
🗓️Klíčové market events of the week: the most important week of the month! This week is full of interesting macroeconomic data and earnings reports from key companies. Here's a summary of the highlights! 👇
🏠Monday: New home sales! Let's keep an eye on how the U.S. housing market is doing, which may indicate the health of consumers and the economy as a whole. 📊 Results before the... Read more
What do you think of today's 20% drop in $NVOstock ? Will you buy?
Novo Nordisk's shares fell sharply today following news that the weight-loss drug CagriSema achieved lower than expected efficacy in trials. I don't have $NVOstock in my portfolio, but I want to focus on this company now.
The company is doing well, but I wouldn't buy the stock as it's a pretty volatile and choppy business. You can see it just on this news alone that one drug will fail and the stock will plummet 20%. I think that's terrible.
In the past month alone, $NVOstock is down more than 11%, and according to the Bulios Fair Price Index, the stock is currently slightly undervalued. Recently @edin_medinmentioned this stock , and frankly I'm starting to think about buying it too. If $NVO stock were to drop another 5, 6%, I would buy.
I recently dissected $NVOhere . I decided to buy shares of this company ahead of its earnings. However, this investment did not work out as I expected. After the mediocre results and the US election results, the stock price rose to $116, however, after a short time it plummeted down to $106. Personally, I expected the price to stay at least at the $110 level, which is where I... Read more
The anti-obesity drug industry was in 2023 valued at $5.6 billion and will exhibit a CAGR of 27% between 2024 and 2032 (expert opinion).
$LLY, $NVO and others are creating drugs like - Ozempic, Wegovy, Mounjaro and Zepbound - These are blockbusters in terms of weight loss market in my opinion. But which companies may have the best chance to take the biggest bite of that... Read more
📆 Overview of interesting things for the upcoming week! 🚀
This week I will be watching mostly company results. With the investor sentiment from last week, I think wonders will happen when the markets announce earnings.
🔍 Monday: ISM Services PMI - This index measures economic activity in the service sector and often serves as an indicator of overall economic health.
Thanks again for the summary, great! The results will certainly be interesting, but more so in the long run. They can't change the market situation this week in my opinion.
I've been buying mostly $AMD now, and a month ago I established a position in $SOFI.